Google
FBIO 株価分析 — Fortress Biotech Inc (Healthcare >> Biotechnology)
FBIO に関するよくある質問
FBIOのPER（株価収益率）は？
Fortress Biotech Inc（FBIO）は現在PER 0.69倍で取引されています。
FBIOのROE（自己資本利益率）は？
Fortress Biotech IncのROEは78.77%です。
FBIOの配当利回りは？
Fortress Biotech Incの配当利回りは0.00%です。
FBIOの品質スコア（Quality Score）は？
当社のAIはFBIOの総合財務品質を100点中77点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
FBIOは今が買い時ですか？
当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
FBIOはどのセクターに属しますか？
Fortress Biotech IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
FBIO AI Analysis Summary
Our AI summary for FBIO: Fortress Biotech Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.69, ROE of 78.77%, a dividend yield of 0.00%. Its financial Quality Score stands at 77/100 — mid-range fundamentals relative to the market. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 2.79
Price
0.07
(2.57%)
Day Change
|
|
|---|
FBIO, ファンダメンタルスコアはgood ( ファンダメンタル = 77) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
平均ROEが低い
ROAがROEに比べて低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not good , and ability to make profit is good , ...
| Deepscope 分析 |
|
64% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
532
|
| Magic Formula Rank by ROE |
532
|
| Magic Formula Rank by ROIC |
409
|
| Price | 2.79 |
| PBV / Sector |
0.45 / 44,105.10
GREAT
|
| Earning Per Share | 3.95 |
| PE / Sector |
0.69 / 19.37
GREAT
|
| PEG or PE/Growth / Sector |
-0.01 / 1.06
|
| Average 1M Daily Value |
2.32 M
GREAT
|
| Average 1W Daily Value |
2.90 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
43% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-06 07:59:58 |
| Symbol | FBIO |
| Name | FORTRESS BIOTECH INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 33.22 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 90.36 / 9,702.21 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1111 Kane Concourse, Bay Harbor Islands, FL, United States, 33154
Phone: 781 652 4500
Website: https://www.fortressbiotech.com
Employees: 78
Sector: Healthcare >> Biotechnology
Description: Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
